Fosun Pharma’s Small Molecule Innovative Drug XH-S004 Achieves Overseas Licensing for a Potential Total of $645 Million
SHANGHAI, Aug. 12, 2025 /PRNewswire/ -- On August 11, Fosun Pharma (SSE:600196, HKEX: 02196) announced that its subsidiary Fosun Pharma Industrial has signed a License Agreement with Expedition Therapeutics Inc.(Expedition) to grant Expedition the rights to develop, manufacture, and commercialize XH-S004, an orally administered dipeptidyl peptidase 1 (DPP-1) inhibitor independently developed by Fosun Pharma, in all regions globally except Chinese...
Intas & Accord signs Agreement to acquire Prothya Biosolutions
AHMEDABAD, India, Aug. 11, 2025 /PRNewswire/ -- Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, has announced the execution of an agreement to acquire 100% of Prothya Biosolutions Belgium BV and each of its subsidiaries, a leading plasma-derived medicinal products (PDMP) business based primarily in the Netherlands and Belgium. Subject to the...
AGEBOX Presents iKids-Growth: Pioneering Safe and Natural Support for Children’s Height Development
RICHMOND, VA., Aug. 11, 2025 /PRNewswire/ -- In the field of pediatric development, a significant advancement is taking shape. For years, parents have navigated a marketplace of nutritional aids—from basic multivitamins to protein powders—with little more than hope to guide them. iKids-Growth marks a meaningful step forward, moving beyond passive nutritional support and toward a more proactive, biologically-informed strategy....
Caliber Enters 25th Year of Empowering Global Pharma with GxP Digital Solutions
HYDERABAD, India, Aug. 11, 2025 /PRNewswire/ -- Caliber, a leading global provider of GxP-compliant digital solutions for the life sciences industry, proudly announces the start of its 25th year of operations. Caliber steps into its 25th year, marking the milestone with the unveiling of its anniversary logo alongside the team...
EVERISE STRENGTHENS LEADERSHIP TEAM WITH CHIEF REVENUE OFFICER AND CHIEF FINANCIAL OFFICER APPOINTMENTS
PLANTATION, Fla., Aug. 11, 2025 /PRNewswire/ -- Everise, a global leader in transforming customer experiences, today announced two senior leadership appointments as the company continues its growth trajectory and expansion in global markets. Industry veteran Robert Jimenez joins as Chief Revenue Officer (CRO), while accomplished finance leader Steven Amaya takes on the role of Chief Financial Officer (CFO). ...
REVEALING STUDY HAS REJUVANT LEADING THE LONGEVITY PACK
Renowned Longevity Researcher Reveals Highlights of New Study to NBJ Conference Guests FERNANDINA BEACH, Fla., Aug. 11, 2025 /PRNewswire/ -- Dr. Brian Kennedy, one of the world's leading Longevity researchers, gave a keynote presentation at the Nutritional Business Journal's annual CEO conference in Palos Verdes CA last week. Dr. Kennedy previewed highlights...
AMI Pharm Advances AYP-101 to Phase 3, Paving the Way for a New Era in Fat-Reduction Injectable drugs
— Novel non-cytolytic injectable drug targets submental fat with significantly reduced pain and swelling— Phase 3 clinical trial underway in South Korea, following strong safety and efficacy results in earlier studies— AMI Pharm positions itself for global expansion in the multi-billion-dollar non-surgical aesthetics market SEOUL, South Korea, Aug. 11, 2025 /PRNewswire/ -- AMI...
“Senior Speed Stack” Introduces Emerging Sport Stacking to Help Reduce Cognitive Decline in the Elderly
Key Points: The Junior Chamber International (JCI) North District organized the "2025 Senior Speed Stack Closing Ceremony," introducing sport stacking to help delay cognitive decline in the elderly. Celebrity Tiffany Lau (Tiffany) participated in speed stacking activities with seniors. Assistant Professor of Teaching Senior Dr Mok Kam-Ming from Lingnan University's School of Interdisciplinary Studies, conducted a tracking study...
Everest Medicines to Announce 2025 Interim Results on August 29, 2025
SHANGHAI, Aug. 11, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will report its interim results for the six months ended June 30, 2025, and provide a business update on August 29, 2025. The Company will hold live...
WuXi Biologics Launches HEK 293 Stable Cell Line Platform WuXia293 Stable for Development and Manufacturing of Difficult-to-Express Molecules
WuXia293Stable platform demonstrates high titer, human glycosylation and improved product quality by eliminating or significantly alleviating truncation in difficult-to-express molecules. WuXia293Stable platform maintains stable expression and consistent product quality during long-term cell passages, enabling scalable clinical and commercial manufacturing. SHANGHAI, Aug. 11, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today...
